Baş-Boyun Adenoid Kistik Karsinomları
Özet
Adenoid kistik karsinom (AKK), tüm baş-boyun tümörlerinin yaklaşık yüzde birini oluşturan ve esas olarak tükrük bezlerinden kaynaklanan nadir, ancak biyolojik olarak son derece yıkıcı ve öngörülemeyen bir malignitedir. Genellikle beşinci ve altıncı dekatlarda ortaya çıkan ve hafif kadın baskınlığı gösteren bu kanser türü, yavaş ilerleyen klinik seyrine tezat oluşturan agresif karakteri, belirgin perinöral invazyon eğilimi, cerrahi sonrası yüksek lokal nüks oranları ve geç dönemde ortaya çıkan uzak metastazları ile karakterizedir. Genomik olarak düşük mutasyon yüküne sahip olan AKK'nın moleküler patogenezinde, vakaların büyük çoğunluğunda saptanan t(6;9) translokasyonu sonucu oluşan MYB-NFIB gen füzyonu ve kötü prognozla ilişkilendirilen NOTCH1 aktivasyonu kritik rol oynamaktadır. Teşhis aşamasında tümörün sınırlarını belirlemek ve perinöral yayılımı değerlendirmek için MRG ve BT gibi ileri görüntüleme yöntemleri tamamlayıcı olarak kullanılır. Metastatik olmayan hastalıkta primer altın standart tedavi yöntemi, negatif sınırlar elde etmeyi amaçlayan radikal cerrahi rezeksiyon ve ardından uygulanan postoperatif radyoterapidir. Buna karşılık, rekürren veya uzak metastaz geliştirmiş ileri evre hastaların yönetiminde geleneksel sitotoksik kemoterapiler ve immünoterapiler oldukça sınırlı bir etkinlik göstermektedir. Günümüzde lenvatinib gibi tirozin kinaz inhibitörleri ve NOTCH yolağını hedefleyen yeni ajanlar, bu ölümcül hastalığın palyatif tedavisinde en umut verici seçenekler olarak klinik araştırmalarda öne çıkmaktadır.
Adenoid cystic carcinoma (ACC) is a rare yet biologically devastating and unpredictable malignancy that primarily originates from the salivary glands, accounting for approximately one percent of all head and neck cancers. Typically diagnosed in the fifth and sixth decades of life with a slight female predominance, this disease is characterized by an indolent but relentless clinical course, a high propensity for perineural invasion, frequent local recurrences even after radical excision, and a strong tendency for late-stage distant metastasis. Genomically characterized by a low mutation burden, its molecular pathogenesis is driven by the hallmark t(6;9) translocation resulting in the MYB-NFIB gene fusion in most cases, alongside NOTCH1 activation associated with poorer outcomes. Diagnostic staging and evaluation of perineural spread rely heavily on the complementary use of MRI and CT imaging. For non-metastatic disease, the therapeutic gold standard remains total surgical resection with negative margins followed by postoperative radiotherapy. Conversely, managing recurrent or metastatic ACC poses significant challenges, as conventional cytotoxic chemotherapy regimens and immunotherapies yield limited clinical efficacy. Currently, targeted agents like lenvatinib and novel NOTCH pathway inhibitors stand out in ongoing clinical trials as the most promising therapeutic avenues to improve outcomes for this lethal disease.
Referanslar
Coca Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck - An update. Oral Oncol 2015; 51(7):652–61.
Ellington CL, Goodman M, Kono SA, et al. Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973–2007 Surveillance, Epidemiology, and End Results data. Cancer 2012;118(18):4444–51.
Cantù G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from aetiopathogenesis to diagnosis. Acta Otorhinolaryngol Ital 2021;41:206-214.
Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res 2021;11(9):4092-4110.
Stell PM: Adenoid cystic carcinoma. Clin Otolaryngol 1986, 11:267–291.
Spies JW: Adenoid cystic carcinoma. Arch Surg 1930, 21:365–404.
Conley J, Dingman DL: Adenoid cystic carcinoma in the head and neck (cyl- indroma). Arch Otolaryngol 1974, 100:81–90.
Jones AS, Hamilton JW, Rowley H, et al.: Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol 1997, 22:434–443.
Stell PM, Cruikshank AH, Stoney PJ, et al.: Adenoid cystic carcinoma: the results of radical surgery. Clin Otolaryngol 1985, 10:205–208.
Spiro RH: Management of malignant tumours of the salivary glands. Oncol- ogy 1998, 12:671–680.
Matsuba HM, Spector GJ, Thawley SE, et al. Adenoid cystic salivary gland carcinoma: a histologic review of treatment failure patterns. Cancer 1986, 57:519–524.
Ranger D, Thackray AC, Lucas RB. Mucous gland tumours. Br J Can- cer 1956;10:1-16.
Supramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Ir J Med Sci. 2015.
Falchook AD, Zevallos JP, Chera BS. Increased risk of salivary gland cancer among women with a previous cancer diagnosis. Head Neck 2016;38(Suppl 1):E446-451.
Simpson RHW, Skálová A, Di Palma S, et al. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465:371–384.
Jaso J, Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med. 2011;135:511–515.
Hellquist H, Skalova A. Histopathology of the Salivary Glands, Chapter 8. Adenoid Cystic Carcinoma. Heidelberg: Springer-Verlag; 2014.
Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984;54:1062–1069.
Badoual C, Baglin AC, Wassef M, et al. Pathologists and the French network of expertise on rare cancers ENT: the REFCORpath. Ann Pathol. 2014;34:64–69.
Van Weert S, Van der Waal I, Witte BI, et al. Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol. 2015;51:71–76.
Edwards PC, Bhuiya T, Kelsch RD. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:613–619.
Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism Curr Opin Otolaryngol Head Neck Surg. 2017;25:147–153.
Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791–798.
Stephens PJ, Davies HR, Mitani Y, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965–2968.
Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(44):18740-18744.
Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8:523–534.
Bernheim A, Toujani S, Saulnier P, et al. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Laboratory investigation; a journal of technical methods and pathology. 2008; 88(5):464-473.
Brill LB, Kanner WA, Fehr A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Modern pathology. 2011; 24(9):1169-1176.
Drier Y, Cotton MJ, Williamson KE, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nature genetics. 2016.
Mitani Y, Liu B, Rao P, et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clinical cancer research. 2015.
Brayer KJ, Frerich CA, Kang H, et al. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer discovery. 2015.
Drabsch Y, Robert RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010;12: R55.
Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000;154:107–11.
Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956–60.
Freier K, Flechtenmacher C, Walch A, et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 2005;41:934–9.
Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009;45:574–8.
Sequeiros-Santiago G, García-Carracedo D, Fresno MF, et al. Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep 2009;21:1215–22.
Sun ZJ, Chen G, Hu X, et al. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 2010;15: 850–63.
Sun ZJ, Chen G, Zhang W, et al. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2- terminal kinase and inhibition of extracellular signal-regulated kinase. J Pharmacol Exp Ther 2010;334:500–12.
Sajed DP, Fawuin WC, Carey C et al. Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is associated with worse outcome in adenoid cystic carsinoma. Am J Surg Pathol. 2017 November ; 41(11): 1473–1482.
Barrera JE, Shroyer KR, Said S, et al. Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer. Head Neck Pathol 2008;2:13–8.
Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 1997;111:1186–9.
Castello A, Olivari L, Lopci E. Adenoid cystic carsinoma: focus on heevy ion therapy and moleculer imaging. Am J Nucl Med Mol Imaging 2018;8(1):1-14
Hong SI, Ahn S, Lee YS, et al. Contrast-induced nephropathy in patients with active cancer undergoing con- trast-enhanced computed tomography. Sup- port Care Cancer 2016; 24: 1011-7.
Freling N, Crippa F, Maroldi R. Staging and fol- low-up of high grade malignant salivary gland tumours: the role of traditional versus func- tional imaging approaches-a review. Oral Oncol 2016; 60: 157-66.
Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol 2010; 28: 1190-1195.
Klein Nulent TJW, Van Es RJJ, Krijger GC, et al. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging 2017; 44: 1614-1621.
Meyers M, Granger B, Herman P, et al. Head and neck adenoid cystic carcinoma: a prospective multicenter REFCOR study of 95 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2016;133:13–17. doi:10.1016/j.anorl.2015.09.009
Amit M, Na’ara S, Trejo-Leider L, et al. Defining the surgical margins of adenoid cystic carcinoma and their impact on outcome: an international collaborative study. Head Neck. 2017;39(5):1008–1014. doi:10.1002/hed.24740
Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32(3):619–26.
Luksic I, Suton P. Elective neck dissection in adenoid cystic carcinoma of head and neck: yes or no? A systematic review. Eur Arch Otorhinolaryngol 2019;276:2957–62.
Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39:1909–1941.
Atallah S, Moya-Plana A, Malard O, et al. Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study. Eur J Cancer. 2020;130:250–258.
Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004;26:154-162.
Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiother- apy in the treatment of malignant salivary gland tumors. Int J Ra- diat Oncol Biol Phys 2005;61:103-111.
Zocchi J, Campa M, Bianchi G, et al. Occult Neck Metastases in Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 4924.
Rodriguez-Russo CA, Junn, JC, Yom SS, et al. Radiation Therapy for Adenoid Cystic Carcinoma of the Head and Neck. Cancers.2021,13,6335.
Atallah S, Marc M, Schernberg A et al. Beyond surgical treatment in adenoid cystic carsinoma of the head and neck: a literatüre review. Cancer Management and Research 2022:14 1879–1890
Lorini L, Ardighieri L, Bozzola A et al. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carsinoma. Oral Oncology 115 (2021) 105213.
Licitra L, Marchini S, Spinazz`e S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991;68(9):1874-1877.
Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. 2002;91(3):541-7.
Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. Ann Oncol 1996;7(6):640–2.
Yusenko MV, Biyanee A, Frank D, et al. Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. Cancers 2021, 14, 43.
Yusenko MV, Biyanee A, Andersson MK, et al. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. Cancer Lett. 2021, 520, 132–142.
Hanna GJ, Oneill A, Cutler JM, et al. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021, 119, 105366.
Andersson MK, Afshari MK, Andrén Y, et al. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling. J. Natl. Cancer Inst. 2017, 109, djx017.
Andersson MK, Mangiapane G, Nevado PT, et al. ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis 2020, 9, 5–10.
Ferrarotto R, Heymach JV, Glisson BS. MYB-fusions and other potential actionable targets in adenoid cystic carsinoma. Curr Opin Oncol. 2016, 28:195-200.
Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23:585– 590.
Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivaryglands. Oral Oncol 2007; 43:33 – 36.
Miller LE, Au V, Mokhtari TE, et al. A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma. Cancers 2022, 14, 992.
Guigay J, Fayette J, Even C, et al. PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC). J. Clin. Oncol. 2016, 34, 6086.
Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2019 Jun 20;37(18):1529–37.
Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 873–898.
Misiorek JO, Przybyszewska-Podstawka A, Kałafut J, et al. Context Matters: NOTCH Signatures and Pathway in Cancer Progression and Metastasis. Cells 2021, 10, 94.
Goleva E, Lyubchenko T, Kraehenbuehl, L, et al. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Ann. Allergy Asthma Immunol. 2021, 126, 630–638.
Sridharan V, Liao X, Chau N, et al. Immunologic profiling of adenoid cystic & carcinoma (acc). 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015). J ImmunTher Cancer 2015; 2015:105.
